A phase I trial of nordihydroguareacetic acid (NDGA) in patients with non-metastatic prostate cancer and rising PSA

被引：0
|
作者：
Harzstark, A. L. [1 ]
Ryan, C. [1 ]
Diamond, M. [1 ]
Jones, J. [1 ]
Zavodovskaya, M. [1 ]
Maddux, B. [1 ]
Claros, C. [1 ]
Goldfine, I. [1 ]
Small, E. J. [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15500
引用
收藏
页数：1
相关论文
共 50 条
  • [1] STAMPEDE trial and patients with non-metastatic prostate cancer
    Gandaglia, Giorgio
    Fossati, Nicola
    Suardi, Nazareno
    Montorsi, Francesco
    Briganti, Alberto
    LANCET, 2016, 388 (10041): : 234 - +
  • [2] SM88 in non-metastatic rising PSA-recurrent prostate cancer.
    Del Priore, Giuseppe
    Sokol, Gerald H.
    Chen, Wen-Tien
    Tsao, Che-Kai
    Hoffman, Steve
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Clinical characteristics and survival outcomes in patients with a high PSA and non-metastatic prostate cancer
    Huang, Cheng-Yu
    Chen, Chung-Hsin
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (01) : 181 - 186
  • [4] A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
    Small, Eric J.
    Fontana, Joseph
    Tannir, Nizar
    DiPaola, Robert S.
    Wilding, George
    Rubin, Mark
    Iacona, Renee Bailey
    Kabbinavar, Fairooz F.
    BJU INTERNATIONAL, 2007, 100 (04) : 765 - 769
  • [5] PSA MONITORING AND RESULTS AMONG MEN WITH NON-METASTATIC PROSTATE CANCER
    Wilson, K. L.
    Foley, K. A.
    VALUE IN HEALTH, 2014, 17 (03) : A96 - A96
  • [6] Effect of docetaxel added to bicalutamide in Hormone-Naive non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)
    Josefsson, Andreas
    Jellvert, Asa
    Holmberg, Erik
    Brasso, Klaus
    Meidahl Petersen, Peter
    Aaltomaa, Sirpa
    Luukkaa, Marjaana
    Verhagen, Paul
    de Wit, Ronald
    Ahlgren, Goeran
    Andren, Ove
    Castellanos, Enrique
    Seke, Mihalj
    Widmark, Anders
    Damber, Jan-Erik
    ACTA ONCOLOGICA, 2023, 62 (04) : 372 - 380
  • [7] Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer
    Gartrell, B.
    Del Priore, G.
    Retter, A.
    Chen, W-T.
    Sokol, G. H.
    Vandell, A.
    Roach, M.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] Phase II trial of SM88 in non-metastatic biochemical recurrent prostate cancer
    Del Priore, G.
    Chen, W-T.
    Dong, H.
    Hoffman, S.
    Sokol, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Randomized phase III trial of thalidomide (Th) or placebo (P) for non-metastatic PSA recurrent prostate cancer (PCa) treated with intermittent therapy
    Figg, W. D.
    Aragon-Ching, J. B.
    Steinberg, S. M.
    Gulley, J. L.
    Arlen, P. M.
    Sartor, O.
    Petrylak, D. P.
    Higano, C. S.
    Hussain, M. H.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer.
    Roach, Mack
    Gostout, Zachary
    Zawisny, Patricia
    Retter, Avi S.
    Sokol, Gerald H.
    Hoffman, Steve
    Del Priore, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345